ENDOTHELIUM-DEPENDENT CONTRACTION IN INTRAPULMONARY ARTERIES - MEDIATION BY ENDOTHELIAL NK1 RECEPTORS AND TXA(2)

被引:30
作者
SHIRAHASE, H [1 ]
KANDA, M [1 ]
KURAHASHI, K [1 ]
NAKAMURA, S [1 ]
USUI, H [1 ]
SHIMIZU, Y [1 ]
机构
[1] TOKAI UNIV,SCH MED,DEPT COMMUNITY HLTH,KANAGAWA 25911,JAPAN
关键词
SUBSTANCE P; INTRAPULMONARY ARTERY; ENDOTHELIUM-DEPENDENT CONTRACTION (EDC); NK1; RECEPTOR; THROMBOXANE A(2) (TXA(2)); NEUROKININ A; NEUROKININ B; NK2;
D O I
10.1111/j.1476-5381.1995.tb15028.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 We have examined whether three natural tachykinins, substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) induce an endothelium-dependent contraction (EDC) in the rabbit isolated intrapulmonary artery. 2 Removal of the endothelium almost abolished the contraction induced by SP (10(-8) M) while it did not attenuate the contraction induced by SP (10(-7) M), NKA (10(-9)-10(-7) M) or NKB (10(-8) and 10(-7) M). 3 The EDC induced by SP (10(-8) M) was abolished by M(1 antagonists (FK-888, CP-96345, CP-99994 and SR-140333) but not by an NK2 antagonist (SR-48968). 4 The EDC induced by SP was attenuated by cyclo-oxygenase inhibitors (aspirin and indomethacin), thromboxane A(2) (TXA(2)) synthetase inhibitors (OKY-046, KY-234 and KY-063) and a TXA(2) antagonist (S-1452). 5 The rank order of potency causing endothelium-independent contraction (EIC) was NKA > NKB > SP. The EIC induced by SP (10(-7) M) was attenuated by an NK2 antagonist but not by NK1 antagonists, cyclo-oxygenase inhibitors, TXA(2) synthetase inhibitors or a TXA(2) antagonist. 6 In conclusion, SP at 10(-8) M induces EDC via endothelial NK1 receptors and TXA(2) production, and SP at 10(-7) M induces EIC via NK2 receptors in the rabbit intrapulmonary artery.
引用
收藏
页码:1215 / 1220
页数:6
相关论文
共 32 条
[1]  
ALLEN KM, 1989, BRIT HEART J, V62, P353
[2]  
ALTIERE RJ, 1986, J PHARMACOL EXP THER, V236, P535
[3]   DISCOVERY OF A POTENT SUBSTANCE-P ANTAGONIST - RECOGNITION OF THE KEY MOLECULAR DETERMINANT [J].
DESAI, MC ;
LEFKOWITZ, SL ;
THADEIO, PF ;
LONGO, KP ;
SNIDER, RM .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (26) :4911-4913
[4]   IN-VITRO AND IN-VIVO BIOLOGICAL-ACTIVITIES OF SR140333, A NOVEL POTENT NONPEPTIDE TACHYKININ NK1, RECEPTOR ANTAGONIST [J].
EMONDSALT, X ;
DOUTREMEPUICH, JD ;
HEAULME, M ;
NELIAT, G ;
SANTUCCI, V ;
STEINBERG, R ;
VILAIN, P ;
BICHON, D ;
DUCOUX, JP ;
PROIETTO, V ;
VANBROECK, D ;
SOUBRIE, P ;
LEFUR, G ;
BRELIERE, JC .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 250 (03) :403-413
[5]   A POTENT AND SELECTIVE NONPEPTIDE ANTAGONIST OF THE NEUROKININ-A (NK2) RECEPTOR [J].
EMONDSALT, X ;
VILAIN, P ;
GOULAOUIC, P ;
PROIETTO, V ;
VANBROECK, D ;
ADVENIER, C ;
NALINE, E ;
NELIAT, G ;
LEFUR, G ;
BRELIERE, JC .
LIFE SCIENCES, 1992, 50 (15) :PL101-PL106
[6]   CHARACTERIZATION OF NK1 AND NK2 TACHYKININ RECEPTORS IN GUINEA-PIG AND RAT BRONCHOPULMONARY AND VASCULAR SYSTEMS [J].
FLOCH, A ;
FARDIN, V ;
CAVERO, I .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 111 (03) :759-768
[7]   PHARMACOLOGICAL PROFILE OF A HIGH-AFFINITY DIPEPTIDE NK1-RECEPTOR ANTAGONIST, FK888 [J].
FUJII, T ;
MURAI, M ;
MORIMOTO, H ;
MAEDA, Y ;
YAMAOKA, M ;
HAGIWARA, D ;
MIYAKE, H ;
IKARI, N ;
MATSUO, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 107 (03) :785-789
[8]   FUNCTIONAL NEUROKININ 1-RECEPTORS FOR SUBSTANCE-P ARE EXPRESSED BY HUMAN VASCULAR ENDOTHELIUM [J].
GREENO, EW ;
MANTYH, P ;
VERCELLOTTI, GM ;
MOLDOW, CF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (05) :1269-1276
[9]   HIGHLY SELECTIVE INHIBITORS OF THROMBOXANE SYNTHETASE .1. IMIDAZOLE DERIVATIVES [J].
IIZUKA, K ;
AKAHANE, K ;
MOMOSE, DI ;
NAKAZAWA, M ;
TANOUCHI, T ;
KAWAMURA, M ;
OHYAMA, I ;
KAJIWARA, I ;
IGUCHI, Y ;
OKADA, T ;
TANIGUCHI, K ;
MIYAMOTO, T ;
HAYASHI, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1981, 24 (10) :1139-1148
[10]  
KANDA M, 1993, JPN J PHARM S, V61